Identification of a novel polyprenylated acylphloroglucinol-derived SIRT1 inhibitor with cancer-specific anti-proliferative and invasion-suppressing activities

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 2128-2136

  Zhu, Lijia ^a   Qi, Ji ^b   Chiao, Christine Ya Chi ^a   Zhang, Qiang ^b   Porco, John A ^b   Faler, Douglas V ^a   Dai, Yan ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

Cancer cell growth; Cancer cell invasion; Polyprenylated acylphloroglucinol; SIRT1 inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; JQ 101; SIRTUIN 1; UNCLASSIFIED DRUG; PHLOROGLUCINOL; SIRT1 PROTEIN, HUMAN; SIRT2 PROTEIN, HUMAN; SIRTUIN 2;

A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CELL AGING; CELL INVASION; CELL SURVIVAL; CELL VIABILITY; CELLS BY BODY ANATOMY; CYTOTOXICITY; DEACETYLATION; DRUG IDENTIFICATION; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; H1299 CELL LINE; HUMAN; HUMAN CELL; IC50; IMMUNOBLOTTING; IN VITRO STUDY; JURKAT CELL LINE; LNCAP CELL LINE; MOUSE; MRC5 CELL LINE; NONHUMAN; PC3 CELL LINE; RAMOS CELL LINE; TUMOR CELL; TUMOR CELL LINE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; NEOPLASMS; PATHOLOGY; TUMOR INVASION;

APOPTOSIS; CELL AGING; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; PHLOROGLUCINOL; SIRTUIN 1; SIRTUIN 2;

EID: 84907225944     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2639     Document Type: Article

References (54)

1. Bordone L and Guarente L: Calorie restriction, SIRT1 and metabolism: Understanding longevity. Nat Rev Mol Cell Biol 6: 298-305, 2005.
2. Inoue T, Hiratsuka M, Osaki M and Oshimura M: The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 6: 1011-1018, 2007.
3. Saunders LR and Verdin E: Sirtuins: Critical regulators at the crossroads between cancer and aging. Oncogene 26: 5489-5504, 2007.
4. Donmez G and Guarente L: Aging and disease: Connections to sirtuins. Aging Cell 9: 285-290, 2010.
5. Bosch-Presegue L and Vaquero A: The dual role of sirtuins in cancer. Genes Cancer 2: 648-662, 2011.
6. Knight JR and Milner J: SIRT1, metabolism and cancer. Curr Opin Oncol 24: 68-75, 2012.
7. Chu F, Chou PM, Zheng X, Mirkin BL and Rebbaa A: Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 65: 10183-10187, 2005.
8. Kojima K, Ohhashi R, Fujita Y, et al: A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun 373: 423-428, 2008.
9. Lee SM, Bae JH, Kim MJ, et al: Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. J Pharmacol Exp Ther 322: 1084-1092, 2007.
10. Liang XJ, Finkel T, Shen DW, Yin JJ, Aszalos A and Gottesman MM: SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res 6: 1499-1506, 2008.
11. Marshall GM, Liu PY, Gherardi S, et al: SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet 7: E1002135, 2011.
12. Suzuki K, Hayashi R, Ichikawa T, et al: SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol Rep 27: 1726-1732, 2012.
13. Gabr AG, Goto H, Hanibuchi M, et al: Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression. Clin Exp Metastasis 29: 207-216, 2012.
14. Byles V, Zhu L, Lovaas JD, et al: SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 31: 4619-4629, 2012.
15. Zhang Y, Zhang M, Dong H, et al: Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene 28: 445-460, 2009.
16. Nakane K, Fujita Y, Terazawa R, et al: Inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145 cells. Int J Urol 19: 71-79, 2012.
17. Holloway KR, Calhoun TN, Saxena M, et al: SIRT1 regulates Dishevelled proteins and promotes transient and constitutive Wnt signaling. Proc Natl Acad Sci USA 107: 9216-9221, 2010.
18. Lovaas JD, Zhu L, Chiao CY, Byles V, Faller DV and Dai Y: SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. Prostate 73: 522-530, 2013.
19. Potente M, Ghaeni L, Baldessari D, et al: SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev 21: 2644-2658, 2007.
20. Potente M and Dimmeler S: Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle 7: 2117-2122, 2008.
21. Jang KY, Hwang SH, Kwon KS, et al: SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 32: 1523-1531, 2008.
22. Huffman DM, Grizzle WE, Bamman MM, et al: SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67: 6612-6618, 2007.
23. Zhao G, Cui J, Zhang JG, et al: SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Gene Ther 18: 920-928, 2011.
24. Cha EJ, Noh SJ, Kwon KS, et al: Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 15: 4453-4459, 2009.
25. DiMeo TA, Anderson K, Phadke P, et al: A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 69: 5364-5373, 2009.
26. Lee H, Kim KR, Noh SJ, et al: Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 42: 204-213, 2011.
27. Chen J, Zhang B, Wong N, et al: Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res 71: 4138-4149, 2011.
28. Kriegl L, Vieth M, Kirchner T and Menssen A: Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget 3: 1182-1193, 2012.
29. Tseng RC, Lee CC, Hsu HS, Tzao C and Wang YC: Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia 11: 763-770, 2009.
30. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M and Sinclair DA: Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 277: 45099-45107, 2002.
31. Grozinger CM, Chao ED, Blackwell HE, Moazed D and Schreiber SL: Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 276: 38837-38843, 2001.
32. Heltweg B, Gatbonton T, Schuler AD, et al: Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 66: 4368-4377, 2006.
33. Solomon JM, Pasupuleti R, Xu L, et al: Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 26: 28-38, 2006.
34. Lain S, Hollick JJ, Campbell J, et al: Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13: 454-463, 2008.
35. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE and Simon JA: Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci USA 98: 15113-15118, 2001.
36. Choi G, Lee J, Ji JY, et al: Discovery of a potent small molecule SIRT1/2 inhibitor with anticancer effects. Int J Oncol 43: 1205-1211, 2013.
37. Lara E, Mai A, Calvanese V, et al: Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 28: 781-791, 2009.
38. Suzuki T, Imai K, Nakagawa H and Miyata N: 2-Anilinobenzamides as SIRT inhibitors. ChemMedChem 1: 1059-1062, 2006.
39. Gey C, Kyrylenko S, Hennig L, et al: Phloroglucinol derivatives guttiferone G, aristoforin, and hyperforin: Inhibitors of human sirtuins SIRT1 and SIRT2. Angew Chem Int Ed Engl 46: 5219-5222, 2007.
40. Zhang Y, Zhang Q, Zeng SX, Zhang Y, Mayo LD and Lu H: Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth. Cancer Biol Ther 13: 915-924, 2012.
41. Qi J and Porco JA Jr: Rapid access to polyprenylated phloroglucinols via alkylative dearomatization-annulation: Total synthesis of (+/-)-clusianone(1). J Am Chem Soc 129: 12682-12683, 2007.
42. Mitasev B and Porco JA Jr: Manganese(III)-mediated transformations of phloroglucinols: A formal oxidative [4 + 2] cycloaddition leading to bicyclo[2.2.2]octadiones. Org Lett 11: 2285-2288, 2009.
43. Zhang Q and Porco JA Jr: Total synthesis of (+/-)-7-epi-nemorosone. Org Lett 14: 1796-1799, 2012.
44. Biber N, Mows K and Plietker B: The total synthesis of hyperpapuanone, hyperibone L, epi-clusianone and oblongifolin A. Nat Chem 3: 938-942, 2011.
45. V aziri H, Dessain SK, Ng Eaton E, et al: HSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159, 2001.
46. Noh SJ, Baek HA, Park HS, et al: Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer. Pathol Res Pract 209: 365-370, 2013.
47. Liu T, Liu PY and Marshall GM: The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 69: 1702-1705, 2009.
48. Li L, Wang L, Li L, et al: Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21: 266-281, 2012.
49. Kalle AM, Mallika A, Badiger J, Alinakhi, Talukdar P and Sachchidanand: Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells. Biochem Biophys Res Commun 401: 13-19, 2010.
50. Sun Y, Sun D, Li F, et al: Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells. Lung Cancer 58: 21-29, 2007.
51. Ota H, Tokunaga E, Chang K, et al: Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25: 176-185, 2006.
52. Huang J, Gan Q, Han L, et al: SIRT1 overexpression antagonizes cellular senescence with activated ERK/S6k1 signaling in human diploid fibroblasts. PLoS One 3: E1710, 2008.
53. Jang SY, Kim SY and Bae YS: P53 deacetylation by SIRT1 decreases during protein kinase CKII downregulation-mediated cellular senescence. FEBS Lett 585: 3360-3366, 2011.
54. Saxena M, Dykes SS, Malyarchuk S, Wang AE, Cardelli JA and Pruitt K: The sirtuins promote Dishevelled-1 scaffolding of TIAM1, Rac activation and cell migration. Oncogene: Dec 23, 2013 (Epub ahead of print).